Article
Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review.
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria - 17 Jul 2022
Miarons Marta, Riera Pau, García-Gil Sara, Gutiérrez-Nicolás Fernando
Abstract excerpt
OBJECTIVE: The purpose of this systematic review is to analyze the published data on the efficacy and safety of doses higher than 180 mg/m2 of irinotecan recommended in the drug's summary of product characteristics in metastatic colorectal cancer patients with genotypes UGT1A1*1/*1 or *1/*28 who are treated with the FOLFIRI regimen. METHOD: A systematic review of the literature was carried out in Medline and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.